Oncology

Patients with BRAF mutations administered treatment with encorafenib/binimetinib trended toward improved and longer responses than patients who received dabrafenib/trametinib.

In preliminary data from the trial evaluating dostarlimab, the results demonstrated that the clinical activity in patients with previously treated recurrent or advanced mismatch repair (MMR)-deficient endometrial cancer had an acceptable safety profile.

The new expanded approval was based on positive results from the phase 3 E1912 study.

Treatment of ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors has a high out-of-pocket cost for patients, with substantial variation among them, according to a study.

A phase 3 trial evaluated nivolumab in combination with ipilimumab in patients with previously untreated MPM and successfully met its primary endpoint of overall survival.

Oncology/Hematology pharmacists from Boston Medical Center discuss how COVID-19 has affected their patients.

The phase 3 trial evaluating nivolumab in combination with cabozantinib demonstrated positive results in the treatment of renal cell carcinoma (RCC).

An interview with Debra Richardson, MD, examined the phase 2 study that included niraparib with bevacizumab for patients with either a complete or partial response after upfront chemotherapy for advanced ovarian cancer.

A protein secreted by fat cells may link obesity and breast cancer, according to a newly published article inTrends in Molecular Medicine.

Cannabis products can counter some negative aspects of chemotherapy.

Patients should be selected for therapy based on the FDA approved companion diagnostic for a trastuzumab product.

The fda has approved talicia (amoxicillin, omeprazole magnesium, and rifabutin) for the treatment of Helicobacter pylori infection in adults.

The FDA does not usually require animalstudies for biosimilars; therefore, the process can move directly to pharmacokinetic and pharmacodynamic studies.

The FDA has granted accelerated approval to pemigatinib (Pemazyre, Incyte Corporation) as the first treatment for adults with certain types of previously treated, advanced cholangiocarcinoma.

This approval is a part of the first Project Orbis partnership between the FDA, Health Sciences Authority, and Swissmedic.

In a population of patients newly diagnosed with ovarian cancer, researchers demonstrated that therapy is well tolerated among both patients who are BRCA-positive and -negative.

Compared with other breast cancer subtypes, TNBC is more likely to be diagnosed in younger women and is more likely to have metastases present at the time of diagnosis.

A protein, known as FOXO1, plays a critical role in heart damage resulting from treatment with the chemotherapy drug anthracycline.

Pharmacists are a rich resource, not only in the management of colorectal cancer, but in every aspect of health care.

The combination of olaparib plus bevacizumab lead to a potentially meaningful improvement in progression-free survival versus olaparib alone in women with BRCA-mutated newly diagnosed ovarian cancer.

In a new study, researchers present their findings of a signaling pathway that could be used in patients with triple-negative breast cancer (TNBC) to enhance therapies in the future.

Importantly, when considering the useof small molecule inhibitors, potential drug interactions must be evaluated.

The mitomycin gel is an alkylating drug, inhibiting the transcription of DNA into RNA and stopping protein synthesis and taking away the cancer cell’s ability to multiply.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

In patients with BRCA wild type carcinomas, treatment with veliparib was beneficial even at low homologous recombination deficiency scores compared with carboplatin and paclitaxel.

The addition of pazoparib to gemcitabine enhances anti-tumor activity, particularly for patients with platinum-resistant disease who derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

A new study investigated the molecular impact of the cancer-killing PARP-1 inhibitor (PARPi) binding to PARP-1 and found that the drug can be structurally modified to increase its power to kill tumor cells.

The results of this study resonate other results, suggesting that 3D mammograms are more accurate than 2D mammograms and may help 3D mammography become part of routine breast cancer screening.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

Approximately 1 in 40 postmenopausal women diagnosed with breast cancer before the age of 65 had a mutation linked to cancer in the BRCA1 or BRCA2 gene, according to an analysis of data from the Women’s Health Initiative (WHI).